Pan-European Survey on the Under Treatment of Hypercholesterolemia

AstraZeneca0 个研究点目标入组 6,500 人开始时间: 2006年1月最近更新: 2007年11月20日

适应症

试验速览

阶段: 不适用
状态: 已完成
发起方: AstraZeneca
入组人数: 6,500
主要终点: The number and percentage of patients achieving the LDL-C goals, according to the Third Joint European Task Force guidelines, overall and by country.

研究概览研究设计入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

The survey try to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines, overall and by country.·

研究设计

研究类型: Observational
时间视角: Prospective

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Patients had to be on a lipid-lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.

排除标准

未提供

结局指标

主要结局

The number and percentage of patients achieving the LDL-C goals, according to the Third Joint European Task Force guidelines, overall and by country.

次要结局

未报告次要终点

研究者

发起方

AstraZeneca

申办方类型

Industry

相似试验

已完成

不适用

Centralized Pan-Russian Survey on the Undertreatment of HypercholesterolemiaDyslipidaemia

NCT01221584AstraZeneca1,000

已完成

不适用

Centralized Pan-Middle East Survey on the Undertreatment of HypercholesterolemiaHypercholesterolemia

NCT01025388AstraZeneca4,053

已完成

不适用

Centralized Pan-Middle East Survey on the Under-treatment of Hypercholesterolemia, Sub-study for the Gulf StatesHypercholesterolemia

NCT01031277AstraZeneca1,000

已完成

不适用

Centralized Pan-Asian Survey on the Under Treatment of HypercholesterolemiaHypercholesterolemia

NCT00687492AstraZeneca8,000

已完成

不适用

Study of Undertreatment of Patients With Dyslipidemia in BulgariaDyslipidemia

NCT01075594AstraZeneca2,500